Pekin Singer Strauss Asset Management IL maintained its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,516 shares of the pharmaceutical company’s stock at the end of the second quarter. Pekin Singer Strauss Asset Management IL’s holdings in GlaxoSmithKline PLC were worth $238,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of GSK. Smith Asset Management Group LP raised its stake in shares of GlaxoSmithKline PLC by 238.2% in the second quarter. Smith Asset Management Group LP now owns 14,700 shares of the pharmaceutical company’s stock valued at $634,000 after buying an additional 10,354 shares during the last quarter. Mondrian Investment Partners LTD raised its stake in shares of GlaxoSmithKline PLC by 7.7% in the second quarter. Mondrian Investment Partners LTD now owns 1,227,806 shares of the pharmaceutical company’s stock valued at $52,943,000 after buying an additional 88,000 shares during the last quarter. First Trust Advisors LP raised its stake in shares of GlaxoSmithKline PLC by 3.2% in the second quarter. First Trust Advisors LP now owns 452,533 shares of the pharmaceutical company’s stock valued at $19,513,000 after buying an additional 14,240 shares during the last quarter. Foundry Partners LLC bought a new stake in shares of GlaxoSmithKline PLC during the second quarter valued at approximately $7,636,000. Finally, National Planning Corp raised its stake in shares of GlaxoSmithKline PLC by 19.1% in the second quarter. National Planning Corp now owns 12,561 shares of the pharmaceutical company’s stock valued at $537,000 after buying an additional 2,013 shares during the last quarter. Institutional investors own 8.96% of the company’s stock.

GlaxoSmithKline PLC (NYSE GSK) opened at 38.79 on Friday. The firm has a 50-day moving average of $41.84 and a 200-day moving average of $41.84. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.59. The stock has a market capitalization of $94.80 billion, a price-to-earnings ratio of 37.51 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. The firm had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. Equities research analysts forecast that GlaxoSmithKline PLC will post $2.85 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a dividend of $0.491 per share. The ex-dividend date is Wednesday, August 9th. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a yield of 5.06%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 197.00%.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/13/pekin-singer-strauss-asset-management-il-has-238000-position-in-glaxosmithkline-plc-gsk.html.

Several equities research analysts have commented on the stock. TheStreet lowered shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research report on Wednesday, July 26th. Citigroup Inc. restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 27th. BidaskClub lowered shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. Finally, Zacks Investment Research lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $44.67.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.